Ryan D. Maynard

Insider Reports History

Identity 1 fact
Location
San Carlos, CA
SEC filing record 1 fact
Filing signature
/s/ Michael LaCascia, Attorney-in-Fact for Ryan D. Maynard
SEC evidence 1 fact
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Ryan D. Maynard:

Form 4 holding Chief Financial Officer

Foghorn Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
400,000
Estimated value
$2,300,000
Report date
23 Feb 2026
Price
$5.75
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding CHIEF FINANCIAL OFFICER

Cara Therapeutics, Inc.

Security class
Common Stock
Shares / value
13,500
Estimated value
$7,425
Report date
01 Feb 2024
Price
$0.5500
Ownership
Direct
Form 4 holding CHIEF FINANCIAL OFFICER

Cara Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
81,000
Estimated value
Report date
01 Mar 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

IOVANCE BIOTHERAPEUTICS, INC.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
12 Nov 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Ryan D. Maynard

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .